PD-L1 Expression in Untreated EGFRm Advanced NSCLC and Response to Osimertinib and SoC EGFR-TKIs in the FLAURA Trial

Simple item page
dc.contributor.authorBrown, H.
dc.contributor.authorVansteenkiste, J.
dc.contributor.authorNakagawa, K.
dc.contributor.authorCobo Dols, M.
dc.contributor.authorJohn, T.
dc.contributor.authorBarker, C.
dc.contributor.authorKohlmann, A.
dc.contributor.authorTodd, A.
dc.contributor.authorSaggese, M.
dc.contributor.authorChmielecki, J.
dc.contributor.authorMarkovets, A.
dc.contributor.authorRamalingam, S.
dc.contributor.authoraffiliation[Brown, H.] Astrazeneca, Labs Precis Med & Genom, Imed Biotech Unit, Cambridge, England
dc.contributor.authoraffiliation[Barker, C.] Astrazeneca, Labs Precis Med & Genom, Imed Biotech Unit, Cambridge, England
dc.contributor.authoraffiliation[Vansteenkiste, J.] Univ Hosp KU Leuven, Resp Oncol Unit Resp Dis, Leuven, Belgium
dc.contributor.authoraffiliation[Nakagawa, K.] Kindai Univ, Sch Med, Dept Med Oncol, Osakasayama, Japan
dc.contributor.authoraffiliation[Cobo Dols, M.] Univ Reg Hosp Malaga, Dept Med Oncol, Ibima, Malaga, Spain
dc.contributor.authoraffiliation[John, T.] Austin Hlth, Olivia Newton John Canc Res Inst, Melbourne, Vic, Australia
dc.contributor.authoraffiliation[Kohlmann, A.] Astrazeneca, Oncol Compan Diagnost Unit, Precis Med & Genom, Imed Biotech Unit, Cambridge, England
dc.contributor.authoraffiliation[Todd, A.] Astrazeneca, Global Med Dev, Biometr & Informat Sci, Cambridge, England
dc.contributor.authoraffiliation[Saggese, M.] Astrazeneca, Global Med Dev, Cambridge, England
dc.contributor.authoraffiliation[Chmielecki, J.] Astrazeneca, Translat Sci, Oncol, Imed Biotech Unit, Waltham, MA USA
dc.contributor.authoraffiliation[Markovets, A.] Astrazeneca, Biosci, Imed Biotech Unit, Waltham, MA USA
dc.contributor.authoraffiliation[Ramalingam, S.] Emory Univ, Sch Med, Winship Canc Inst, Hematol & Med Oncol, Atlanta, GA USA
dc.date.accessioned2025-01-07T12:18:54Z
dc.date.available2025-01-07T12:18:54Z
dc.date.issued2018-10-01
dc.identifier.doi10.1016/j.jtho.2018.08.441
dc.identifier.essn1556-1380
dc.identifier.issn1556-0864
dc.identifier.unpaywallURLhttp://www.jto.org/article/S1556086418313996/pdf
dc.identifier.urihttps://hdl.handle.net/10668/24449
dc.identifier.wosID454014501078
dc.issue.number10
dc.issue.numberS
dc.journal.titleJournal of thoracic oncology
dc.journal.titleabbreviationJ. thorac. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.page.numberS408-S408
dc.publisherElsevier science inc
dc.rights.accessRightsopen access
dc.titlePD-L1 Expression in Untreated EGFRm Advanced NSCLC and Response to Osimertinib and SoC EGFR-TKIs in the FLAURA Trial
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number13
dc.wostypeMeeting Abstract

Files

Collections

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía